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Summary The possible effect of lithium chloride, a compound which reduces the incidence of infection in
cancer patients, was investigated on murine melanoma. C57 BL syngeneic mice were inoculated i.p. with B16
melanoma cells. The animals were divided into 4 groups, receiving daily i.p. treatment with saline-group 1,
controls; lithium chloride-group 2; bleomycin and vinblastine-group 3, and lithium chloride with bleomycin
and vinblastine-group 4. Animals in group 4 had a significant delay in tumour appearance, a higher degree
of tumour necrosis, and a longer survival rate. In addition a significant reduction of serum lithium
concentration was noted in animals of this group in comparison with animals in group 2, treated with lithium
chloride alone. There was no lithium-induced leukocytosis.
It has been previously reported that the
administration of lithium to patients with
malignancies, treated with chemotherapeutic drugs
is associated with a reduced incidence of infection
and infection-related death (Charron, 1979; Levitt
et al., 1980; Lyman et al., 1980 and Stein et al.,
1979). This beneficial effect has been attributed to
the elevated white blood counts observed in
patients treated with lithium, which in turn, have
been related to the stimulatory effect of this ion on
pluripotent stem cells in the bone marrow (Levitt,
1980). No data on the possible effect of lithium
either on tumour size or on the time of appearance
of tumours have been presented to date. In view of
its heterogeneous action on different tissues
(Bjotum, 1975; Baran et al., 1978) we investigated
the leukocyte count, tumour size, time of
appearance of the tumour and the survival rate in
melanoma-bearing mice on chemotherapy alone
and on combined treatment with chemotherapy and
lithium.
Materials and methods
The experiments were carried out in C57 BL adults
female syngeneic mice, kept 10 to a cage in the
animal house of the "Life Sciences Faculty", at Tel-
Aviv University. Animals were divided into 4
groups, consisting of 10 mice each. Each mouse
was inoculated i.p. in the right gluteal region, with
106 B16 melanoma cells, obtained from Dr. J.I.
Fidler, Frederick, Maryland, U.S.A. Animals in
group 1 were maintained on daily i.p. injections of
isotonic saline, 0.5ml. and are henceforth referred
to as controls. Animals in group 2 had daily i.p.
injections of lithium chloride (Merck Co.,
Germany) 3m eqKg-1. Animals in group 4 were
treated by daily i.p. injections of lithium chloride as
in group 2 in addition to the i.p. injections of
Bleomycin and Vinblastine as in group 3. This was
found to be the most effective mode of treatment of
B16 melanoma-bearing mice (Mabel et al., 1978;
Stephens et al., 1978). All 4 modalities of treatment
were started one day after the inoculation with
melanoma cells and maintained till death. Mice
were examined daily and tumour presence was
established by palpation.
One day before the inoculation of tumour cells
and on the 14th and 28th days of treatment a blood
sample was obtained from the ophthalmic venous
plexus and white blood cell count and serum
lithium concentration determined. In animals of
groups 2 and 4, the blood sample was taken 4h
after the daily i.p. injection of lithium. Upon death,
animals were weighed and the tumour was excised.
Tumour excision, morphometric and histological
studies were carried out by a senior pathologist
(RG) who was unaware of the mode of treatment
of the various animals. Tumour tissue was
identified by melanoma-induced discoloration, and
excised manually from the surrounding normal
tissue. After weighing, tumours were fixed in 10%
formol-alcohol and benzol solution and embedded
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in paraffin. Approximately 10 sections, 5gm thick
each, were cut throughout the depth of the tumour
and stained with hematoxylin and eosin. A
transparent plastic grid with equidistant points,
1 mm apart, was placed over the sections. Each
point was scored as either necrotic or tumour
tissue. The fraction of necrotic tissue was calculated
as a percentage of the cross section. Data are
expressed as a mean of all studied sections
(Thurlbeck et al., 1970. Dunill point count). The
spleens were cultured for bacterial growth using
blood agar medium, MacConkey medium and
Thioglycollate Broth medium.
Serum concentrations of lithium were determined
by Instrumentation Laboratory, Flame Photometer
343. Lithium tissue concentrations were determined
by Optical Emission Spectroscopy (I. Schoenfeld,
personal communication). Statistical analysis was
performed by the student's t test and data are
expressed as means + s.d.
tumour appearance was observed in Group 3, when
compared to groups 1 and 2 (P<0.05), and group 4
differed significantly in this parameter from group 3
(P<0.05) and from groups 1 and 2 (P<0.01).
Duration of survival is graphically presented in
Figure 2. Mean survival was 21.5+3.9; 23.25+2.18;
30.9+4.01 and 38+6.0 days for groups 1, 2, 3 and
4 respectively. No significant differences in this
parameter were observed between Groups 1 and 2,
however, each of these 2 groups differed
significantly from either group 3 or 4 (P<0.01);
groups 3 and 4 also differed significantly from one
another (P<0.05). White blood cell counts
determined on days 0, 14 and 28 of the study are
presented in Table I. A significant increase in white
blood count (P<0.01) was observed in groups 1
and 2 on the 14th day, but there was no significant
difference between the two groups. No significant
change in WBC count was observed in groups 3
and 4 on the 14th day; however, by the 28th day,
WBC count increased significantly in both groups.
10.
Results
There were no differences in body wt among mice
in the 4 groups at the time of death. The mean and
standard deviations of weights were 22.7+2.9;
24.5+2.37; 23.5+2.55 and 22.8+2.15g for Groups
1, 2, 3 and 4 respectively.
A tumour mass was palpable in all mice in
groups 1 and 2 by the tenth day, in group 3 by the
22nd day, and in group 4 by the 34th day (Figure
1). The mean time of tumour appearance in each
group was 6.0+1.9; 6.6+1.9; 12.2+5.3 and
23.4+9.6 days in groups 1, 2, 3 and 4 respectively.
Groups 1 and 2 did not differ significantly from
each other in this respect, while significant delay in
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Figure 1 Time interval between inoculation with B16
melanoma cells and appearance of tumour. Animals of
group 1 ( ) received NaCl solution; animals of
group 2 (----) received lithium chloride; animals of
group 3 (--) were treated with Bleomycin and
Vinblastine and those of group 4 (- -) were treated
with lithium as well as the two chemotherapeutic
agents.
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Figure 2 Duration of survival. Duration of survival
in mice from the 4th (- *-) group is significantly
longer (P<0.05) than that of mice from group 3 (--)
and much longer (P<0.01) than that of mice from
group I( )or2(----).
Table I White blood cell count (mm-3) on days 0, 14
and 28 in the four experimental groups.
Day
Group 0 14 28
1 10,800-2,500 22,900-11,060*
2 9,400-1,800 19,400-10,910*
3 9,640-1,630 12,200- 6,430 20,780- 9,180*
4 7,900-1,520 9,200- 2,500 37,800-18,400*
WBC Counts on day 14 in Groups 1 and 2 are not
significantly different from those observed on day 28 in
Groups 3 and 4.
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WBC counts on day 14 in groups 1 and 2 were not
significantly different from those observed on day
28 for Groups 3 and 4.
Data on tumour wt and on percentage of tumour
tissue necrosis are presented in Table II. Tumour
wt was significantly smaller in Groups 3 and 4
when compared to either Group 1 or Group 2. No
significant differences in this parameter were
observed between Group 1 and Group 2 or between
Group 3 and Group 4. The fraction of tumour
tissue necrosis compared to the total tumour mass
was similar in Groups 1, 2 and 3, whereas group 4
had a significantly higher degree of tumour necrosis
in comparison with any of the other 3 groups.
Lithium serum concentrations are presented in
Figure 3: The mean concentration on the 14th day
in mice in Group 2 was 0.58+0.06meql1-; the
mean concentration on the 14th and 28th day in
mice of Group 4 was 0.20+0.22meql1-. These
values differ significantly from each other
(P<0.01). No significant difference was observed in
serum lithium concentrations in Group 4 mice
between the 14th and the 28th days. All spleen
cultures were negative.
Table II
per cent
groups.
Mean total weight of tumour and
necrosis in the four experimental
Group Tumour wt (g) % necrosis
1 4.62-2.27 68.5-27.4
2 3.96-2.36 66.5-30.6
3 2.67-1.17* 65 -31.4
4 2.25-0.49* 85 -17.8+
Tumour wt is significantly smaller in
Groups 3 and 4*. The % tumour tissue
necrosis is higher in group 4+.
*P<0.01 compared to either Groups or 2.
'P00 compared to groups 1, 2 or 3.
Lithium concentrations in the tumour masses
were: 0.666+0.009; 0.78+0.38; 0.051+0.010 and
0.312+0.16meqkg-1 in groups 1, 2, 3 and 4
respectively.
Discussion
Lithium has been applied widely in the treatment of
patients on systemic chemotherapy for various
malignancies. It has been suggested that the
reduction in infection-related morbidity and
mortality rates in patients treated with lithium was
due to a relative leukocytosis induced by the
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Figure 3 Lithium concentrations in serum. Mean
concentrations on the 14th day (0) in mice of the 2nd
group was higher than that measured in mice of the
4th group, both on the 14th day (0) and on the 28th
day (0).
lithium (Charron, 1979; Levitt et al., 1980; Lyman
et al., 1980; Stephens et al., 1978). To our
knowledge the direct effect of lithium on tumour
size or time of appearance has not yet been
investigated. In our experimental model we used a
combination of vinblastine and bleomycin. This
mode oftreatment was found to be superior to other
combinations such as bleomycin/cis-platinum, 5
Fluorouracil/BCNU and 5 Fluorouracil/methyl
CCNU in the treatment of B16 melanoma in mice
(Mabel et al., 1978).
The cytotoxic effect of bleomycin is observed
primarily in cells during mitosis and the G2 phase.
Vinblastine, by disrupting the mitotic spindle
temporarily increases the population of cells in the
mitotic phase. Therefore it has been speculated that
a combination of these two agents may have a
more potent cytotoxic effect than that observed
when each agent is used alone (Mabel et al., 1978).
The combined treatment with both cytotoxic drugs
and lithium chloride in melanoma-bearing mice
produced in our hands a significant delay in
tumour appearance, a higher degree of tumour
necrosis and a longer survival rate. These effects
cannot obviously be related directly to the lithium
itself, since mice treated with lithium alone did not
differ in any one of the parameters from control
animals. It has been previously demonstrated that
lithium, by a possible interaction with cellular
membrane proteins, may produce changes in
membrane fluidity, thus increasing the transport of86 A. BALLIN et al.
various amino acids (Kayama et al., 1976).
Furthermore, the administration of lithium has
been associated with a prolonged response to
various anaesthetic agents (Hill et al., 1977;
Reimherr et al., 1977). Thus lithium possibly
enhances the penetration of cytotoxic agents into
the cell by virtue of changes in membrane
permeability, indirectly potentiating their cytotoxic
properties, delaying tumour appearance and
increasing the degree of tumour cell necrosis. Pre-
treatment with lithium has been associated with
higher incidence, more rapid progression and a
larger mean tumour mass in mice treated with
methyl cholantrene (Messiha et al., 1979). This
finding, too, may be interpreted as an increased
lithium-induced cellular penetration of methyl
cholantrene, enabling the carcinogen to act on
cellular elements. Although most mice in group 4
demonstrated a significant delay in tumour
appearance and a longer duration of survival, some
did not differ in these parameters from mice in
Groups 1, 2 and 3. No apparent cause for this
heterogeneity could be detected. This phenomenon
may possibly reflect biological differences in host-
tumour-therapy relationships. Tumour size on
death was considerably smaller in animals of group
4; it seems therefore that tumour size per se was
not the sole cause of death in these mice.
Treatment-induced deaths cannot be excluded in
this population.
A significant leukocytosis following tumour
inoculation was observed in all experimental
groups. Whereas leukocytosis was already apparent
in Groups 1 and 2 by the 14th day, it was
significantly delayed in Groups 3 and 4. Since
tumour appearance was also delayed in the two
latter groups it seems likely that the leukocytosis in
our experiment is related to the growth of the
tumour itself and not to the mode of treatment. In
contrast to studies performed in humans or dogs
(Charron, 1979; Levitt et al., 1980; Lyman et al.,
1980; Stein et al., 1979; Hammond et al.,1980) we
did not observe lithium-induced-leukocytosis. It is
not clear whether this difference between our study
and those of other investigators reflects species
differences or other unknown factors. However, a
similar degree of leukocytosis in mice on cytotoxic
agents alone, and in those on combined cytotoxic
and lithium therapy precludes consideration of
leukocytosis per se as the factor determining the
duration of survival. Lithium serum concentrations
were significantly lower in mice treated with
combined lithium and chemotherapy, in
comparison with those treated with lithium alone.
Since the lithium ion is excreted predominantly by
the kidney (Trauner et al., 1955; Donker et al.,
1979) and the tumour concentration is in
equilibrium with that in serum, we can assume that
the cytotoxic drugs used by us caused an increase
in urinary excretion of lithium probably by
reducing the tubular reabsorption of this ion. We
conclude, therefore, that the addition of lithium to
chemotherapy in melanoma-bearing mice is
associated with both a delay in tumour appearance
and significantly prolonged duration of survival.
Survival of these animals seems to be independent
of the degree of leukocytosis. The combined
treatment with lithium and these chemotherapeutic
agents is associated with a significant reduction of
serum lithium concentration, thus implying the
necessity for constant monitoring of serum
concentration of lithium when this ion is given as
an adjuvant to chemotherapy in various malignant
conditions.
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